- Home
- AYTU vs CARM Comparison
AYTU vs CARM Comparison
Compare AYTU & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- CARM
- Stock Information
- Founded
- AYTU N/A
- CARM 2016
- Country
- AYTU United States
- CARM United States
- Employees
- AYTU N/A
- CARM N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- CARM Health Care
- Exchange
- AYTU Nasdaq
- CARM Nasdaq
- Market Cap
- AYTU 9.6M
- CARM 8.4M
- IPO Year
- AYTU N/A
- CARM N/A
- Fundamental
- Price
- AYTU $2.10
- CARM $0.42
- Analyst Decision
- AYTU
- CARM Hold
- Analyst Count
- AYTU 0
- CARM 5
- Target Price
- AYTU N/A
- CARM $0.90
- AVG Volume (30 Days)
- AYTU 624.8K
- CARM 42.1M
- Earning Date
- AYTU 05-14-2025
- CARM 08-07-2025
- Dividend Yield
- AYTU N/A
- CARM N/A
- EPS Growth
- AYTU N/A
- CARM N/A
- EPS
- AYTU N/A
- CARM N/A
- Revenue
- AYTU $81,659,000.00
- CARM $19,964,000.00
- Revenue This Year
- AYTU N/A
- CARM N/A
- Revenue Next Year
- AYTU $8.68
- CARM N/A
- P/E Ratio
- AYTU $11.39
- CARM N/A
- Revenue Growth
- AYTU 0.41
- CARM 32.45
- 52 Week Low
- AYTU $0.95
- CARM $0.14
- 52 Week High
- AYTU $2.96
- CARM $1.90
- Technical
- Relative Strength Index (RSI)
- AYTU 60.77
- CARM 52.02
- Support Level
- AYTU $1.97
- CARM $0.41
- Resistance Level
- AYTU $2.17
- CARM $0.56
- Average True Range (ATR)
- AYTU 0.14
- CARM 0.13
- MACD
- AYTU 0.00
- CARM -0.01
- Stochastic Oscillator
- AYTU 58.33
- CARM 20.33
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.